KUALA LUMPUR, March 31 (Bernama) -- The Digital Therapeutics Alliance (DTA), a global non-profit trade association is hosting its three-day Inaugural Summit at the Washington Marriott at Metro Center, beginning June 7.
Leaders from all facets of the digital therapeutics (DTx) ecosystem, including policymakers, clinicians and payors, will join DTA members to discuss the challenges and opportunities of DTx integration into the healthcare system and identify optimised policy, reimbursement and regulatory pathways to accelerate adoption.
The Summit programming will be facilitated by DTA Chief Executive Officer, Andy Molnar and feature keynote presentations, panel discussions and interactive sessions covering the advancement of DTx, the impact of healthcare policy, reimbursement and regulatory pathways, clinical evidence requirements, as well as patient access optimisation.
“We are here to transform healthcare and deliver a new category of medicine to patients to improve their lives. The 2023 DTA Inaugural Summit brings together the leaders in healthcare innovation that are making these monumental changes.
“We are building viable frameworks with partners from Capitol Hill, the investment ecosystem, clinicians, health plans, patients and caregivers,” said Molnar in a statement.
DTx products use evidence-based, clinically evaluated technologies to optimise clinical and health economic outcomes, deliver high quality therapies to underserved populations and transform how patients understand, manage and engage in their healthcare.
Leading into the Summit, US-focused DTA members and staff will convene in Washington D.C. to meet with congressional members and other influential parties to advocate for the Access to Prescription Digital Therapeutics Act (S. 723 and H.R. 1458).
This bill seeks to create a new benefit category for digital therapeutics and ensure permanent coverage and reimbursement of DTx products by Medicare and Medicaid.
-- BERNAMA
No comments:
Post a Comment